Biohaven Therapeutics
As of the edition of 20 October 2026, Biohaven Therapeutics runs 11 drugs, 1 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 8 |
| Stopped | 1 |
| Status not established | 1 |
| Total | 11 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Rimegepant | Ends 2034 (patent) | 0 |
A route B row is one company at one target.
Where its trials are
- Nervous system: 18 trials led
- Mental health: 9 trials led
- Immune system: 4 trials led